肾移植受者新型冠状病毒肺炎的流行病学特征：单中心回顾性研究

Epidemiological characteristics of SARS-CoV-2 pneumonia in kidney transplant recipients : a single-center retrospective study

    摘要
  • 摘要:
      目的  探讨肾移植受者新型冠状病毒肺炎（新冠肺炎）的流行病学特征，分析新型冠状病毒（新冠病毒）感染重型/危重型的危险因素及保护因素。
      方法  回顾性分析感染新冠病毒的468例肾移植受者的临床资料，按感染严重程度分为新冠病毒感染轻型受者（439例）和新冠肺炎组（29例）。将439例新冠病毒感染轻型受者按性别、年龄、移植时间与新冠肺炎组以3∶1进行随机配比的87例受者分为新冠病毒感染轻型组。将29例新冠肺炎组受者分为新冠肺炎中型组（21例）及新冠肺炎重型/危重型组（8例）。收集受者一般资料，分析肾移植受者新冠病毒感染的危险因素及保护因素。
      结果  新冠肺炎组受者合并症种类2～3种的比例高于新冠病毒感染轻型组，新冠肺炎组受者采用他克莫司（Tac）+咪唑立宾+糖皮质激素免疫抑制方案的比例低于新冠病毒感染轻型组，差异均有统计学意义（均为P<0.05）。29例新冠肺炎组肾移植受者患新冠肺炎后白细胞、淋巴细胞绝对值、嗜酸性粒细胞绝对值、总T细胞绝对值、CD4+T细胞绝对值、CD8+T细胞绝对值及血尿酸较患新冠肺炎前明显下降，铁蛋白水平升高，差异均有统计学意义（均为P<0.05）。与新冠肺炎中型组比较，重型/危重型组受者低氧血症的比例更高，采用Tac/环孢素（CsA）+霉酚酸酯+糖皮质激素免疫抑制方案的受者比例更高，接种2～3针新型冠状病毒疫苗（新冠疫苗）者比例更少，差异均有统计学意义（均为P<0.05）。
      结论  肾移植受者合并症多、使用含霉酚酸酯的免疫抑制方案是新冠病毒感染的危险因素，接种新冠疫苗、使用含咪唑立宾的免疫抑制方案可能是降低新冠病毒感染率的保护因素，炎症因子水平与新冠肺炎的严重程度相关。

     

    Abstract:
      Objective  To investigate the epidemiological characteristics of SARS-CoV-2 pneumonia in kidney transplant recipients and analyze the risk and protective factors of severe/critical infection with SARS-CoV-2.
      Methods  Clinical data of 468 kidney transplant recipients infected with SARS-CoV-2 were retrospectively analyzed. According to the severity of infection, they were divided into mild SARS-CoV-2 infection recipients (n=439) and SARS-CoV-2 pneumonia group (n=29). Among the 439 mild SARS-CoV-2 infection recipients, 87 recipients who were randomly matched with their counterparts in the SARS-CoV-2 pneumonia group according to sex, age and transplantation time at a ratio of 3∶1 were allocated into the mild SARS-CoV-2 infection group. Twenty-nine recipients in the SARS-CoV-2 pneumonia group were divided into the moderate SARS-CoV-2 pneumonia group (n=21) and severe/critical SARS-CoV-2 pneumonia group (n=8). Baseline data of all recipients were collected. The risk and protective factors of SARS-CoV-2 infection in kidney transplant recipients were identified.
      Results  The proportion of recipients complicated with 2-3 types of complications in the SARS-CoV-2 pneumonia group was higher than that in the mild SARS-CoV-2 infection group, and the proportion of recipients treated with tacrolimus(Tac)+mizoribine+glucocorticoid immunosuppression regimen in the SARS-CoV-2 pneumonia group was lower than that in the mild SARS-CoV-2 infection group, and significant differences were observed (both P<0.05). In 29 kidney transplant recipients with SARS-CoV-2 pneumonia in the SARS-CoV-2 pneumonia group, white blood cells, the absolute values of lymphocytes, eosinophils, total T cells, CD4+T cells and CD8+T cells, and serum uric acid levels were significantly lower, whereas ferritin levels were significantly higher than the values prior to SARS-CoV-2 pneumonia, and significant differences were observed (all P<0.05). Compared with the moderate SARS-CoV-2 pneumonia group, the proportion of recipients with hypoxemia was higher, the proportion of recipients treated with Tac/ciclosporin (CsA)+mycophenolate mofetil+glucocorticoid immunosuppression regimen was higher, and the proportion of recipients administered with 2-3 doses of SARS-CoV-2 vaccine was lower in the severe/critical SARS-CoV-2 pneumonia group, and significant differences were observed (all P<0.05).
      Conclusions  More complications and immunosuppression regimen containing mycophenolate mofetil are the risk factor for SARS-CoV-2 infection in kidney transplant recipients. Vaccination with SARS-CoV-2 vaccine and immunosuppression regimen containing mizoribine are probably the protective factors for lowering the risk of SARS-CoV-2 infection. The levels of inflammatory cytokines are associated with the severity of SARS-CoV-2 pneumonia.

     

    • HTML全文
    • 参考文献(35)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回